Chau Quang Khuong has bought stock on 5 days since May 2018

Khuong Chau Quang (also known professionally as Chau Q. Khuong) is a biotech entrepreneur and healthcare venture capital investor who serves as a Director and 10% owner of Galecto, Inc. (GLTO), where he has reported significant insider transactions in the company’s securities.( At Galecto he has participated in major financing activities, including a notable purchase of shares in November 2020, reflecting a substantial long‑term investment position in the company.( He is therefore a Person (individual) corporate insider, not a firm or institution.(

Khuong’s broader career spans more than two decades in life sciences venture capital and company building. From 2003 to 2021, he was a Partner at OrbiMed Advisors, a global healthcare‑dedicated investment firm, where he served on the investment committee for its venture capital funds and led investments across drug development and medical device enterprises in areas such as oncology, infectious diseases, ophthalmology, gene therapy, and gene editing.( He has served on the boards of numerous public and private companies—including Arius Research, BELLUS Health, Durata, Fusion Pharma, Glaukos Medical, Intellia, Intercept, Inspire Medical Systems, NextCure, Otonomy, Pieris, Rempex, and ReViral—highlighting his role as a key strategic advisor in the biotech and medtech sectors.( Khuong holds a B.S. in molecular, cellular and developmental biology with a biotechnology concentration and an M.P.H. in infectious diseases, both from Yale University, providing a scientific and public‑health foundation for his investment and board work.(

Written by Perplexity from public sources.